Vectors Research Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vectors Research Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-125	Closed	-$35K	–	474
2022 Q2	$35K	Hold	125	–	–	0.01%	249
2022 Q1	$33K	Sell	125 -135	-52%	-$32K	0.01%	254
2021 Q4	$57K	Buy	260 +135	+108%	+$26.3K	0.01%	251
2021 Q3	$23K	Hold	125	–	–	0.01%	299
2021 Q2	$25K	Hold	125	–	–	0.01%	299
2021 Q1	$27K	Hold	125	–	–	0.01%	263
2020 Q4	$30K	Hold	125	–	–	0.01%	236
2020 Q3	$34K	Buy	+125	New	+$34.5K	0.01%	197

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vectors Research Management's VRTX Position: Q3 2022 in Review

Vectors Research Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 125 shares — an estimated $35K sold.

Vectors Research Management first reported a position in VRTX in Q3 2020 and held it in 8 quarters. The position peaked at $57K in Q4 2021. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Vectors Research Management reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Vectors Research Management sold 125 Vertex Pharmaceuticals shares in Q3 2022, an estimated $35K.
Vectors Research Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 8 quarters.
Vectors Research Management's Vertex Pharmaceuticals position peaked at $57K in Q4 2021.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.